Immunomodulatory Small Molecules


Cambridge Healthtech Institute 第1回
免疫調節低分子医薬品
がん免疫療法に対応する低分子医薬品の創薬と開発

第15回Discovery on Targetの一翼を担うイベント

免疫調節低分子医薬品をテーマにしたこのシンポジウムでは、免疫調節薬の創薬と開発に携わっている主要な研究者が一堂に会し、新たな標的や新規免疫調節阻害剤について意見を交換するとともに、チェックポイント抗体との併用に関する前臨床研究と臨床研究の成果などを披露します。

Final Agenda


RECOMMENDED ALL ACCESS PACKAGE:

· September 25 Symposium: Immunomodulatory Small Molecules 

· September 25 Short Course: Immunology Basics for Chemists 

· September 26-27 Conference: NK Cell-Based Cancer Immunotherapy 

· September 27-28 Conference: Targeting Tumor Myeloid Cells 

· September 27 Short Course: Impact of Convergence of Immunotherapy and Epigenetics on Drug Discovery 

· September 28-29 Symposium: Tackling Rare Diseases 


Monday, September 25

7:00 am Registration Open and Morning Coffee

KINASE AND EPIGENETIC INHIBITORS FOR CANCER IMMUNOTHERAPY

7:55 Welcome Remarks

Kip Harry, Senior Conference Director, Cambridge Healthtech Institute

8:00 Chairperson's Opening Remarks

Jonathan Pachter, Ph.D., CSO, Translational Research, Verastem

8:10 Immunologic Effects of Clinical Stage FAK and PI3K-Delta/Gamma Inhibitors

Jonathan Pachter, Ph.D., CSO, Translational Research, Verastem

The efficacy and long term survival observed with our FAK inhibitor in combination with PD-1 antibody across preclinical models has led to 3 ongoing clinical trials combining our FAK inhibitor defactinib with anti-PD-1 and anti-PD-L1 in solid tumor indications. Additionally, in preclinical models, PI3K-delta inhibition has been shown to confer selective inhibition of Tregs, while PI3K-gamma inhibition confers selective inhibition of MDSCs. Accordingly, immuno-oncology applications of our Phase III PI3K-delta/gamma inhibitor duvelisib will be discussed.

8:40 Preclinical Development of G1T38

Jay Strum, Ph.D., CSO, G1 Therapeutics

9:10 A Novel Dual PI3K/BRD4 Inhibitor, SF2523 for Combinatorial Activation of Anti-Tumor Immunity in Cancer Via the Orthogonal Inhibition of MYCN and MYC

Donald Durden, M.D., Professor, Department of Pediatrics, University of California, San Diego

We have developed a dual inhibitory chemotype which blocks MYC via two orthogonal independent pathways: 1) PI3K inhibition induces MYCN degradation and 2) BRD4 blocks MYCN transcription. We demonstrate that this small molecule, SF2523, blocks MYCN transcription and induces MYCN degradation and abrogates the macrophage immunosuppressive effects on tumor immunity via the blockade of the M1-M2 transition in vivo.

9:40 Networking Coffee Break with Poster Viewing

10:10 A First-in-Class Selective Class IIa Histone Deacetylase (HDAC) Inhibitor, TMP195

Michael Nolan, Ph.D., Director, GlaxoSmithKline

We recently reported that a first-in-class selective class IIa HDAC inhibitor (TMP195) influenced human monocyte responses to colony stimulating factors CSF-1 and CSF-2 in vitro. Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumor microenvironment and reduces tumor burden and pulmonary metastases through macrophage modulation. TMP195 induces recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumors.

10:40 Selective HDAC6 Inhibitors

Steven Quayle, Ph.D., Associate Director, Oncology, Acetylon Pharmaceuticals, Inc.

11:10 Sponsored Presentation (Opportunity Available)

11:40 Enjoy Lunch on Your Own

SMALL MOLECULES TARGETING PD-1, IDO1, TDO2, AND STING

1:10 pm Chairperson's Remarks

Lijun Sun, Ph.D., Associate Professor, Harvard Medical School; Director, Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center

1:20 Design and Synthesis of IDO1 and TDO2 Inhibitors

Lijun Sun, Ph.D., Associate Professor, Harvard Medical School; Director, Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center

We conducted in silico screens to identify novel and selective IDO1 and TDO2 inhibitors, respectively. Enzymatic hIDO1 and hTDO2 assays were utilized to confirm inhibitory activity and selectivity. Among the confirmed inhibitors, a series of oxan-4-carboxamides selectively inhibited hIDO1, while a series of substituted 9H-fluorenes were identified as TDO2 selective inhibitors (IC50: 1 µM). In this presentation, we will discuss the in silico approach and provide updates on characterization data of the inhibitors.

1:50 Development of SB 11285, a Highly Potent STING Agonist for Application in Immuno-Oncology

R.P. (Kris) Iyer, Ph.D., Co-Founder & CSO, Spring Bank Pharmaceuticals

Immunotherapy has emerged as a transformative approach for the treatment of cancer. Evidence suggests that the activation of Stimulator of Interferon Genes (STING) pathway in tumor cells and/or immune cells induces type I Interferon production leading to apoptosis of tumor cells as well as induction of adaptive immune response thereby providing a powerful anti-cancer strategy. Herein, we describe the discovery of highly potent and selective first-in-class STING agonist SB 11285 for application in immuno-oncology.

2:20 A Novel Small Molecule to Target PD-1/PD-4 and MUC 16 and MUC 4 in Cancer Immunotherapy

Krishna Menon, Ph.D., Scientific Advisor, Research & Development, AR Biosystems

AR Biosystems has developed NCEs to treat cancer and other related conditions affecting PD-1, PD-4, MUC 4 and MUC 16.

2:50 Networking Refreshment Break with Poster Viewing

NOVEL IMMUNOMODULATORY SMALL MOLECULES

3:30 Selective Activation of Toll-Like Receptor 7 and 8 in the Design of Cancer Vaccines

David Ferguson, Ph.D., Professor, Medicinal Chemistry, University of Minnesota

The basic structural features of small molecule ligands that confer selectivity to Toll-like receptors 7 and 8 will be discussed in the context of immunomodulation and the design of cancer vaccines. An SAR analysis will be presented to identify structural features that confer selectivity to TLR7 and TLR8 and ligand specific activation of key cytokines in producing antigen specific cellular responses in model systems. Finally, in vivo data will be shown that demonstrates the potential of TLR7/8 stimulation in designing advanced vaccines for cancer treatment.

4:00 Anti-Cancer Therapy by Inducing Immunogenicity in Tumors with Small Molecules

Weiwen Ying, Ph.D., Co-Founder and President, Drug Discovery, Capten Therapeutics

Capten Therapeutics is developing a new class of drugs that enhance the immunogenicity of cancer cells in a novel way. Our technology uses analogs of the active substance in natural produces to bond with proteins in cancer cells to produce highly immunogenic haptenated proteins. These haptenated proteins stimulate an adaptive immune response that opens the door to effective therapeutic options.

4:30 Novel Natural Immunomodulatory Peptide Synergistic with Chemotherapy

Raghu Pandurangi, Ph.D., Founder & President, Drug Design, Sci-Engi-Medco Solutions, Inc.

Loss of immunity protein beta defensin is responsible for the onset of cancer. A fragment of beta defensin modulates immunofunction which when delivered selectively to cancer cells resulted in the regression of tumor. The peptide fragment also synergizes with standard FDA-approved chemotherapeutics in vitro/in vivo. This novel peptide can be used as neoadjuvant to chemotherapy to expand the therapeutic index of existing treatments.

5:00 Close of Symposium

5:00 Pre-Conference Dinner Short Course Registration

Click here for details on short courses offered.

 

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English

カタログダウンロード
カタログ(PDF)


Celebrating 25 Years

Submit A Poster

View All Sponsors

View Media Partners



メール配信サービス